Lamivudine for the treatment of HIV

被引：30

作者：

Kumar, Princy N. ^{[1
]}

Patel, Parul ^{[2
]}

机构：

[1] Georgetown Univ, Div Infect Dis, Washington, DC 20007 USA

[2] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA

来源：

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2010年 / 6卷 / 01期

关键词：

antiretroviral therapy; HIV; lamivudine; nucleoside reverse transcriptase inhibitor; IMMUNODEFICIENCY-VIRUS-INFECTION; ZIDOVUDINE COMBINATION THERAPY; TENOFOVIR DISOPROXIL FUMARATE; CHRONIC HEPATITIS-B; CD4 CELL COUNTS; ANTIVIRAL ACTIVITY; INITIAL TREATMENT; RESISTANT VIRUS; NAIVE PATIENTS; ABACAVIR;

D O I：

10.1517/17425250903490418

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Lamivudine is a nucleoside reverse transcriptase inhibitor that is widely used for the treatment of HIV-1 infection in combination with other antiretrovirals. It is a highly effective agent that can be dosed once or twice daily due to its long intracellular half-life. it also has one of the best tolerability and long-term safety profiles among all antiretroviral agents and continues to be preferred as part of initial or subsequent combination therapy in HIV-infected patients.

引用

页码：105 / 114

页数：10

共 66 条

[1]

Aboulker JP, 2002, LANCET, V359, P733

[2]

AlFaraidy K, 1997, TRANSPLANTATION, V64, P926

[3]

[Anonymous], 1996, Lancet, V348, P283, DOI 10.1016/S0140-6736(96)05387-1

[4]

[Anonymous], ANT THER HIV INF AD

[5] Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients - 144-week analysis [J].

Arribas, Jose R. ;

Pozniak, Anton L. ;

Gallant, Joel E. ;

DeJesus, Edwin ;

Gazzard, Brian ;

Campo, Rafael E. ;

Chen, Shan-Shan ;

McColl, Damian ;

Holmes, Charles B. ;

Enejosa, Jeffrey ;

Toole, John J. ;

Cheng, Andrew K. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (01) :74-78

[6] Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection [J].

Bartlett, JA ;

Benoit, SL ;

Johnson, VA ;

Quinn, JB ;

Sepulveda, GE ;

Ehmann, WC ;

Tsoukas, C ;

Fallon, MA ;

Self, PL ;

Rubin, M .

ANNALS OF INTERNAL MEDICINE, 1996, 125 (03) :161-+

[7] Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors [J].

Birkus, G ;

Hitchcock, MJM ;

Cihlar, T .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :716-723

[8] Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection [J].

Campbell, TB ;

Shulman, NS ;

Johnson, SC ;

Zolopa, AR ;

Young, RK ;

Bushman, L ;

Fletcher, CV ;

Lanier, ER ;

Merigan, TC ;

Kuritzkes, DR .

CLINICAL INFECTIOUS DISEASES, 2005, 41 (02) :236-242

[9] Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study) [J].

Castagna, A ;

Danise, A ;

Menzo, S ;

Galli, L ;

Gianotti, N ;

Carini, E ;

Boeri, E ;

Galli, A .

AIDS, 2006, 20 (06) :795-803

[10]

Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3

← 1 2 3 4 5 6 7 →